CAS NO: | 528-43-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Magnolol, a natural lignan isolated from the stem bark ofMagnolia officinalis, is a dual agonist of bothRXRαandPPARγ, withEC50values of 10.4 μM and 17.7 μM, respectively. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | Magnolol is a dual agonist of both RXRα and PPARγ, with EC50values of 10.4 μM and 17.7 μM, respectively. Magnolol (26.2-80 μM) binds to RXRαLBD and PPARγLBD in a dose dependent manner, with Kdvalues of 45.7 μM and 1.67 μM, respectively. Magnolol (1-20 μM) induces the transcription of PPRE in a dose-dependent manner, but shows no activity on RXRE transcription[1]. Magnolol (1, 3, 10 μM) enhances adipocyte differentiation of both 3T3-L1 pre-adipocystes and C3H10T1/2 pluripotent stem cells in the presence of insulin. Magnolol (10 μM) upregulates mRNA expression of marker genes for adipocyte differentiation. Magnolol (1, 10 μM) shows an increase in basal and insulin-stimulated glucose uptake in differentiated 3T3-L1 adipocytes[2]. | ||||||||||||||||
体内研究 (In Vivo) | Magnolol (5-15 mg/kg, p.o.) significantly attenuates the phenotypic severity of dextran sulfate sodium (DSS)-induced colitis in mice. Magnolol (10, 15 mg/kg, p.o.) attenuates histopathological changes and myeloperoxidase activity in the colon of DSS-treated mice, decreases DSS-induced high levels of proinflammatory cytokines TNF-α, IL-1β and IL-6 in the colonic tissues. Magnolol (10 mg/kg, p.o.) also reverses abnormality of serum metabolome, and regulates tryptophan metabolic pathway in mice[3]. | ||||||||||||||||
分子量 | 266.33 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C18H18O2 | ||||||||||||||||
CAS 号 | 528-43-8 | ||||||||||||||||
中文名称 | 厚朴酚 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(375.47 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|